As of June 7, 2025, Turning Point Therapeutics Inc (TPTX) reports a EV/EBITDA of -8.38.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Turning Point Therapeutics Inc's EV/EBITDA to Peers
To better understand Turning Point Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Turning Point Therapeutics Inc (TPTX) | -8.38 |
| TG Therapeutics Inc (TGTX) | 91.92 |
| Amicus Therapeutics Inc (FOLD) | 43.02 |
| Abbvie Inc (ABBV) | 18.25 |
| Amgen Inc (AMGN) | 15.22 |
| Regeneron Pharmaceuticals Inc (REGN) | 14.93 |
Compared to its competitors, Turning Point Therapeutics Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.